Joan Gilmore
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Joan Gilmore has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Alexander C. Huang
Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
24 shared publications - Amanda Cervini
Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
24 shared publications - Amy Marshall
Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
24 shared publications - Andrea Brennan
Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
24 shared publications - Carl H. June
University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States
24 shared publications - E. John Wherry
Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, USA
24 shared publications
Latest Publications
- Open Access
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
TABLE 1 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
TABLE 1 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 1 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
TABLE 1 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
- Open Access
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
TABLE 4 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
MRNA signals corresponding to CAR T cells in peripheral blood
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 4 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
MRNA signals corresponding to CAR T cells in peripheral blood
- Open Access
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 2 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
IHC analysis of CD8 in preinfusion and postinfusion tumor tissue. Three subjects had preinfusion and postinfusion tumor tissue available for analysis; postinfusion tumor tissue demonstrated an increase in cytoxic CD8+ cells in all 3 subjects.
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 2 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
IHC analysis of CD8 in preinfusion and postinfusion tumor tissue. Three subjects had preinfusion and postinfusion tumor tissue available for analysis; postinfusion tumor tissue demonstrated an increase in cytoxic CD8+ cells in all 3 subjects.
- Open Access
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
TABLE 4 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
MRNA signals corresponding to CAR T cells in peripheral blood
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 4 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
MRNA signals corresponding to CAR T cells in peripheral blood
- Open Access
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
TABLE 5 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
IHC analysis of paired tumor tissue
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 5 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
IHC analysis of paired tumor tissue
- Open Access
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
TABLE 5 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
IHC analysis of paired tumor tissue
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 5 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
IHC analysis of paired tumor tissue
- Open Access
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
Supplementary Figure 2: Representative immunohistochemical staining for Subject 27 with metastatic triple-negative breast cancer; lymph node biopsy. Panel A shows CD8 staining prior to infusion and Panel B shows CD8 staining at the time of post-infusion biopsy.
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
Supplementary Figure 2: Representative immunohistochemical staining for Subject 27 with metastatic triple-negative breast cancer; lymph node biopsy. Panel A shows CD8 staining prior to infusion and Panel B shows CD8 staining at the time of post-infusion biopsy.
- Open Access
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
Supplementary Figure 1.: Representative immunohistochemical staining for Subject 74 with metastatic melanoma; lymph node biopsy. Panel A: pS6 staining prior to infusion; Panel B: pS6 staining at post-infusion biopsy; Panel C: Ki-67 staining prior to infusion; Panel D: Ki-67 staining at post-infusion biopsy.
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
Supplementary Figure 1.: Representative immunohistochemical staining for Subject 74 with metastatic melanoma; lymph node biopsy. Panel A: pS6 staining prior to infusion; Panel B: pS6 staining at post-infusion biopsy; Panel C: Ki-67 staining prior to infusion; Panel D: Ki-67 staining at post-infusion biopsy.
- Open Access
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 2 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
IHC analysis of CD8 in preinfusion and postinfusion tumor tissue. Three subjects had preinfusion and postinfusion tumor tissue available for analysis; postinfusion tumor tissue demonstrated an increase in cytoxic CD8+ cells in all 3 subjects.
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 2 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
IHC analysis of CD8 in preinfusion and postinfusion tumor tissue. Three subjects had preinfusion and postinfusion tumor tissue available for analysis; postinfusion tumor tissue demonstrated an increase in cytoxic CD8+ cells in all 3 subjects.
- Open Access
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 1 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
Study procedures. Participant study procedures including cell collection/manufacturing timeline as well as infusion schedule from eligibility confirmation onward.
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 1 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
Study procedures. Participant study procedures including cell collection/manufacturing timeline as well as infusion schedule from eligibility confirmation onward.